TickerFacts.

Company research / NUS

Nu Skin Enterprises, Inc. (NUS)

Build a valuation ↗↓ Download CSV

SEC name NU SKIN ENTERPRISES, INC. · CIK 0001021561 · NYSE · Wholesale-Drugs, Proprietaries & Druggists' Sundries

  • Sector Wholesale Trade
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Nu Skin Enterprises, Inc. reported revenue of $1.49B. Revenue fell 14.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $1.38B.

Key ratios (year ended 2025-12-31)

69.4%
Gross margin
4.4%
Operating margin
10.8%
Net margin
19.9%
Return on year-end equity
-14.3%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-10

Headquarters locality: Provo · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$1.38B$1.49B$1.73B$1.97B$2.23B$2.70B$2.58B$2.42B$2.68B$2.28B$2.21B
Cost of Revenue$423.76M$453.76M$550.23M$611.85M$630.91M$675.22M$658.03M$581.42M$634.14M$502.08M$500.46M
Gross Profit$951.49M$1.03B$1.18B$1.36B$1.59B$2.02B$1.92B$1.84B$2.04B$1.78B$1.71B
R&D Expensen/a$10.80M$13.00M$22.60M$23.30M$27.20M$23.30M$30.10M$23.00M$22.00M$24.30M
Operating Income-$10.41M$65.76M-$151.59M$48.27M$110.85M$233.99M$257.56M$267.43M$240.86M$274.48M$231.10M
Depreciation & Amortization$50.00M$52.26M$69.81M$70.92M$72.51M$76.32M$73.99M$76.65M$83.00M$71.56M$72.40M
EBITDA$39.60M$118.02M-$81.78M$119.19M$183.35M$310.31M$331.56M$344.08M$323.86M$346.05M$303.50M
Net Income-$216.39M$160.20M-$146.59M$8.60M$104.78M$147.27M$191.35M$173.55M$121.89M$129.44M$143.09M
EPS (Diluted)n/a$3.18-$2.95$0.17$2.07$2.86$3.63$3.10$2.16$2.36$2.55
Total Assets$1.12B$1.41B$1.47B$1.81B$1.82B$1.91B$1.96B$1.77B$1.69B$1.59B$1.47B
Total Liabilities$578.79M$600.07M$817.46M$986.66M$923.67M$993.71M$1.06B$893.72M$912.58M$885.28M$809.98M
Shareholders' Equity$542.74M$805.24M$651.46M$821.97M$897.30M$912.77M$894.27M$875.29M$781.87M$704.60M$664.07M
Cash & Equivalents$189.64M$238.63M$186.88M$256.06M$264.73M$339.59M$402.68M$335.63M$386.91M$426.40M$357.25M
Operating Cash Flow$50.81M$80.29M$111.74M$118.64M$108.06M$141.58M$379.14M$177.93M$202.74M$302.56M$275.26M
Capital Expenditures$40.03M$34.28M$41.58M$58.49M$59.06M$68.61M$63.82M$66.07M$70.37M$60.16M$50.22M
Free Cash Flow$10.78M$46.01M$70.16M$60.15M$49.01M$72.97M$315.32M$111.86M$132.37M$242.40M$225.04M
Share Repurchases$20.04M$20.04M$0$13.01M$70.05M$80.42M$144.33M$825.0K$69.56M$71.73M$247.21M
Dividends Paid$11.65M$11.83M$11.93M$77.62M$77.02M$76.27M$78.39M$82.19M$80.58M$76.06M$78.44M
Weighted Average Diluted Sharesn/a50.30M49.66M49.86M50.52M51.43M52.77M55.93M56.48M54.85M56.10M
EPS (Basic)n/a$3.25-$2.95$0.17$2.10$2.93$3.66$3.13$2.21$2.45$2.58

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView